Mazdutide
GLP-1/glucagon agonist approved in China for diabetes and obesity — still in early FDA review stages.
Last Verified: August 14, 2026
Tier 2 — Investigational / Not Currently Approved Late-Stage Investigational
Mazdutide is not FDA-approved in the United States, though it has large completed Phase 3 trials and full regulatory approval in China. This page describes the mechanism and trial data — not dosing or usage guidance, and not a recommendation to use it. Talk to a doctor before considering it.
What It Is
Mazdutide (also known by its development code IBI362) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics, working through the same two-receptor mechanism concept as survodutide — GLP-1 activity for appetite and insulin effects, glucagon-receptor activity for added energy expenditure.
What the Trials Actually Show
Mazdutide's clinical program has run primarily in Chinese populations. The Phase 3 GLORY-1 trial, in 610 Chinese adults, showed roughly 13% placebo-subtracted weight reduction at the 6 mg dose by week 32. A second Phase 3 trial, GLORY-2, evaluated a 9 mg dose in Chinese adults with obesity and reported up to 20.1% weight loss, meeting its primary and all key secondary endpoints. This is real, completed Phase 3 data — it just hasn't yet been generated or reviewed in a US population or through the FDA process.
Innovent — Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults, GLORY-2 Study →
Current Regulatory Status
China's National Medical Products Administration (NMPA) has approved mazdutide for both glycemic control in type 2 diabetes and for obesity — making it, per Innovent, the first GLP-1/glucagon dual agonist to receive full regulatory approval for obesity anywhere in the world. In the US, however, mazdutide has not been submitted to or approved by the FDA for any indication; as of this writing, US development is reported to still be in Phase 2 trials, with Phase 3 expected in 2026–2027 and an FDA filing not anticipated until 2027–2028 at the earliest. In practice: approved medicine in China, unapproved investigational compound in the US — a genuinely different regulatory status depending on where you are, and neither status transfers to the other.